Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States.
Division of Child and Adolescent Psychiatry, Massachusetts General Hospital, Boston, MA, United States.
Psychiatry Res. 2022 Feb;308:114347. doi: 10.1016/j.psychres.2021.114347. Epub 2021 Dec 20.
Cannabidiol (CBD) has become a fast-growing avenue for research in psychiatry, and clinicians are challenged with understanding the implications of CBD for treating mental health disorders. The goal of this review is to serve as a guide for mental health professionals by providing an overview of CBD and a synthesis the current evidence within major psychiatric disorders. PubMed and PsycINFO were searched for articles containing the terms "cannabidiol" in addition to major psychiatric disorders and symptoms, yielding 2952 articles. Only randomized controlled trials or within-subject studies investigating CBD as a treatment option for psychiatric disorders (N = 16) were included in the review. Studies were reviewed for psychotic disorders (n = 6), anxiety disorders (n = 3), substance use disorders (tobacco n = 3, cannabis n = 2, opioid n = 1), and insomnia (n = 1). There were no published studies that met inclusion criteria for alcohol or stimulant use disorder, PTSD, ADHD, autism spectrum disorder, or mood disorders. Synthesis of the CBD literature indicates it is generally safe and well tolerated. The most promising preliminary findings are related to the use of CBD in psychotic symptoms and anxiety. There is currently not enough high-quality evidence to suggest the clinical use of CBD for any psychiatric disorder.
大麻二酚 (CBD) 在精神病学研究中迅速发展，临床医生面临着理解 CBD 治疗精神健康障碍的影响的挑战。本综述的目的是通过提供 CBD 的概述和主要精神障碍中的当前证据的综合，为精神健康专业人员提供指导。在 PubMed 和 PsycINFO 上搜索了包含术语“大麻二酚”以及主要精神障碍和症状的文章，共产生了 2952 篇文章。只有将 CBD 作为治疗精神障碍的选择进行随机对照试验或个体研究（N=16）的文章才包含在综述中。对精神障碍（n=6）、焦虑障碍（n=3）、物质使用障碍（烟草 n=3、大麻 n=2、阿片类 n=1）和失眠（n=1）的研究进行了综述。没有发表的研究符合酒精或兴奋剂使用障碍、创伤后应激障碍、注意力缺陷多动障碍、自闭症谱系障碍或情绪障碍的纳入标准。对 CBD 文献的综合分析表明，它通常是安全且耐受良好的。最有希望的初步发现与 CBD 在精神病症状和焦虑中的应用有关。目前没有足够的高质量证据表明 CBD 可用于任何精神障碍的临床应用。
